Skip to main content

Table 3 Comparisons of neurological status and clinical outcome between IS patients with and without EPO treatment

From: Effect of erythropoietin on level of circulating endothelial progenitor cells and outcome in patients after acute ischemic stroke

Variables

Group 1† (n= 83)

Group 2† (n= 84)

P- value*

NIHSS at 48 h

6.78 ± 4.60

7.35 ± 7.55

0.562

Modified Rankin Scale score at 48 h

3.23 ± 1.38

2.89 ± 1.62

0.152

Barthel Index at 48 h

55.7 ± 30.5

59.5 ± 36.0

0.467

NIHSS on day 90

4.27 ± 5.39

5.49 ± 7.77

0.239

Recurrent stroke, % (n)

0% (0)

9.5% (8)

0.007

90-day mortality, % (n)

2.4% (2)

1.2% (1)

0.621

Primary end point, % (n)‡

2.4% (2)

10.7% (9)

0.057

NIHSS ≥ 8.0

14.5% (12)

29.8% (25)

0.017

Combined MANE, % (n)¶

16.9% (14)

36.9% (31)

0.004

  1. *: by Chi-square test or Fisher's exact test for categorical data; by t-test for continuous data.
  2. †: group 1 = with EPO treatment; group 2 = without EPO treatment.
  3. ‡: defined as 90-day combined recurrent stroke or death.
  4. ¶: MANE = major adverse neurological event (defined as NIHSS ≥8, recurrent stroke or death on Day 90 after acute IS).
  5. IS, ischemic stroke; NIHSS, national institutes of health stroke scale.